Pfizer has suspended research into its weight-loss drug.  Undesirable side effects in patients

Pfizer has suspended work on its experimental weight-loss pill. The drug was taken twice daily and produced effects and a number of side effects, including nausea and diarrhea. Despite the failure, the company does not want to give up work in the pharmaceutical market sector, which is worth tens of billions of dollars. He concluded that it was necessary to reduce the frequency of doses of the drug tested.

Pfizer conducted research on Experimental slimming pills. Obese patients take it twice a day, as recommended. It turned out that the drug worked and that people lost weight, but it began to appear in most people A number of unwanted diseases.

See: Pfizer sues Poland for huge sum. Billions of zlotys in fines for not collecting vaccines

626 people participated in the second phase of the study. They mainly complained Digestive system problems. Most of them suffered from nausea, diarrhea and vomiting. The company said most complaints were mild Does not pose a threat to patient safety.

As reported by cnbc.com, the pharmaceutical company made the announcement on Friday Stop taking danoglibron. The drug will not enter the third phase of testing at the present time, but the company intends to test its effects when the frequency of administration is reduced to once a day. It plans to publish a report on the results next year.

Pfizer loses in the stock market. Patients complained of side effects

After announcing the results of the second stage. Pfizer’s stock price fell five percent in one day.

The slimming drug market is worth it 90 billion dollars. Pfizer had hoped to become one of the major players in it, but experts are pessimistic about the company’s potential when it comes to this sector.

SEE: Covid is back. “Vaccination is really the only antidote.”

in June The company rejected other weight loss pills, which was administered once daily. Unfortunately, the drug did not work, and elevations in liver enzymes were recorded in patients using it. Friday’s data moved the company further away from achieving its intended goal of dominating the market by producing effective and safe weight-loss products.

Read more

Want to stay up to date with the latest news?

We’re in the app for your phone. Check us out!

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

100 Richest Poles 2023 Forbes. List of the richest residents of Lodz County! The Foreman brothers are the richest on February 25, 2023

On Thursday, February 23, Forbes published the latest list of the 100…

1963! From this year come the engines, the production of which is being restored in Russia

The engines will be used in GAZ buses and trucks from Nizhny…

Scandal in the Netherlands! The ex-minister became a member of the Gazprom pressure group

After Cora van Nieuwenhuizen resigned from her ministerial position and became a…

Polsat News Plus Play P4 Court ruling News ticker Mobile operator channel Events Announcement of apology

For several days, just before 6:50 p.m., Polsat News’ program “Wydarzenia” was…